“T cell engagers have the potential to transform outcomes for people living with autoimmune diseases and cancer, and emerging clinical data underscore their promise as a compelling therapeutic modality. We look forward to sharing initial clinical data for CLN-978 and velinotamig throughout 2026. CD19 and BCMA are now well-validated autoimmune targets, and by addressing both, we aim to comprehensively treat more diseases and redefine standards of care for more patients with these two clinical-stage programs. Similarly, the early success of CLN-049 in AML further reinforces the remarkable promise of T cell engagers in many high unmet need disease settings across immunology and oncology,” said Nadim Ahmed, President and CEO of Cullinan Therapeutics (CGEM).
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Cullinan jumps after UCB acquires Candid Therapeutics
- Cullinan Oncology: FDA Acceptance of Zipalertinib NDA and Upcoming CLN-978 Data Underpin Buy Rating and Favorable NPV Outlook
- Cullinan Therapeutics price target raised to $30 from $27 at H.C. Wainwright
- Cullinan Therapeutics announces U.S. FDA accepted NDA for zipalertinib
- Clear Street says Gilead-Ouro deal highlights upside for Cullinan’s velinotamig